Should I buy or sell Mesoblast stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. View MESO analyst ratings or view top-rated stocks .

What is Mesoblast's stock price target for 2024?

6 Wall Street research analysts have issued twelve-month price objectives for Mesoblast's shares. Their MESO share price targets range from $3.00 to $34.00. On average, they expect the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 164.3% from the stock's current price. View analysts price targets for MESO or view top-rated stocks among Wall Street analysts .

How have MESO shares performed in 2024?

Mesoblast's stock was trading at $2.20 at the start of the year. Since then, MESO stock has increased by 135.0% and is now trading at $5.17. View the best growth stocks for 2024 here .

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,340,000 shares, an increase of 190.1% from the March 15th total of 806,500 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is presently 1.1 days. View Mesoblast's Short Interest .

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our MESO earnings forecast .

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) announced its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The firm had revenue of $2.14 million for the quarter, compared to the consensus estimate of $2 million.

When did Mesoblast's stock split?

Shares of Mesoblast reverse split on Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Exelixis (EXEL) , CRISPR Therapeutics (CRSP) , Novavax (NVAX) , Micron Technology (MU) , Vaxart (VXRT) and AbbVie (ABBV) .

When did Mesoblast IPO?

Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MESO

Mesoblast (MESO) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free MESO Stock Alerts

$5.17

-0.20 (-3.72%)

(As of 04/15/2024 ET)

Compare

Today's Range: $5.13
▼
$5.54
50-Day Range: $1.79
▼
$6.59
52-Week Range: $1.61
▼
$10.24

Volume: 290,037 shs
Average Volume: 1.96 million shs
Market Capitalization: $589.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Get Mesoblast alerts:

Mesoblast MarketRank™ Stock Analysis

Analyst Rating: Hold
2.17 Rating Score
Upside/Downside: 164.3% Upside
$13.67 Price Target
Short Interest: Healthy
2.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.71) to ($0.60) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

551st out of 929 stocks

Biological Products, Except Diagnostic Industry

88th out of 148 stocks

3.1

Analyst's Opinion

Consensus Rating
Mesoblast has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Mesoblast has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.05% of the outstanding shares of Mesoblast have been sold short.
Short Interest Ratio / Days to Cover
Mesoblast has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Mesoblast has recently increased by 190.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Mesoblast does not currently pay a dividend.
Dividend Growth
Mesoblast does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MESO.

3.1

News and Social Media Coverage

News Sentiment
Mesoblast has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Mesoblast this week, compared to 2 articles on an average week.
Search Interest
27 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
MarketBeat Follows
14 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mesoblast insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.43% of the stock of Mesoblast is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Mesoblast are expected to grow in the coming year, from ($0.71) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mesoblast is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mesoblast is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mesoblast has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

To get all the details of this controversial tech – click here now.

About Mesoblast Stock (NASDAQ:MESO)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MESO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MESO Stock News Headlines

April 13, 2024 | americanbankingnews.com

Mesoblast (NASDAQ:MESO) Shares Down 2.9%

April 12, 2024 | americanbankingnews.com

Mesoblast Limited (NASDAQ:MESO) Given Consensus Rating of "Hold" by Brokerages

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 10, 2024 | seekingalpha.com

Mesoblast Limited: Back From The Dead

April 5, 2024 | msn.com

Why is everyone talking about Mesoblast shares?

April 4, 2024 | finance.yahoo.com

Spinal Fusion Pipeline Report 2024, Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

April 3, 2024 | msn.com

Fed members back cutting rates this year, but need confidence inflation slowing

April 3, 2024 | investorplace.com

Feeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 3, 2024 | au.investing.com

Top ASX Stocks for this Month

April 2, 2024 | fool.com.au

Mesoblast share price dumps 10% as excitement simmers on FDA submission

April 2, 2024 | au.investing.com

What is next for Tesla stock after soft Q1 sales report

April 1, 2024 | fool.com.au

Blast off! Mesoblast share price surging 60%

March 31, 2024 | fool.com.au

Top ASX shares to buy in April 2024

March 29, 2024 | finance.yahoo.com

Aohua receives Endoscopy Award at Healthcare Asia Medtech Awards 2024

March 28, 2024 | morningstar.com

Mesoblast Ltd LWB

March 27, 2024 | afr.com

ASX retreats ahead of CPI; Mesoblast soars 45pc

March 27, 2024 | msn.com

iBio, ImmunityBio, Mesoblast among healthcare movers

March 26, 2024 | msn.com

FDA Commentary Sends Biotech Soaring During Premarket Hours

March 26, 2024 | marketwatch.com

Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application

March 26, 2024 | fool.com.au

Mesoblast share price rockets 36% on breaking FDA news

March 26, 2024 | afr.com

ASX slips as tech declines; Mesoblast soars 47pc

March 26, 2024 | markets.businessinsider.com

FDA Indicates Adequate Data For Mesoblast's Remestemcel-L BLA Submission In Children With SR-aGVHD

March 25, 2024 | globenewswire.com

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

March 20, 2024 | finance.yahoo.com

MESO Jan 2025 0.500 call

March 19, 2024 | finance.yahoo.com

MESO Oct 2024 2.000 call

March 19, 2024 | finance.yahoo.com

MESO Jul 2024 2.000 put

See More Headlines

Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/30/2023
Today: 4/15/2024
Next Earnings (Estimated): 5/23/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:MESO
Previous Symbol: OTCMKTS:MBLTY
CUSIP: N/A
CIK: 1345099
Web: www.mesoblast.com
Phone: (139) 639-6036
Fax: 61-3-9639-6030
Employees: 83
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.67
High Stock Price Target: $34.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +164.3%
Consensus Rating: Hold
Rating Score (0-4): 2.17
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 2.71
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $7.50 million
Price / Sales: 78.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.16 per share
Price / Book: 0.84

Miscellaneous

Outstanding Shares: 114,070,000
Free Float: 92,626,000
Market Cap: $589.74 million
Optionable: Optionable
Beta: 3.59

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Silviu Itescu FACP (Age 67)
FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Comp: $738.74k
Dr. Eric A. Rose M.D. (Age 73)
Chief Medical Officer & Executive Director
Comp: $625.46k
Mr. Andrew Chaponnel B.Com.
Interim Chief Finance Officer
Mr. Peter T. Howard B.Sc. (Age 56)
L.L.B., LLB (Hons), General Counsel & Corporate Executive
Mr. Roger D. Brown BA
Head of Spinal Orthopedic Disorders
Mr. Michael Schuster BSc (Age 47)
M.B.A., MS, Head of Pharma Partnering
Ms. Geraldine Storton B.Sc.
M.B.A., MMS, Head of Regulatory Affairs & Quality Management
Mr. Justin Horst B.S.
Head of Manufacturing
Ms. Niva Sivakumar B.Com.
L.L.B., Joint Company Secretary
Mr. Paul Hughes BPHARM
Joint Company Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MESO Stock Analysis - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings or view top-rated stocks.
What is Mesoblast's stock price target for 2024?: 6 Wall Street research analysts have issued twelve-month price objectives for Mesoblast's shares. Their MESO share price targets range from $3.00 to $34.00. On average, they expect the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 164.3% from the stock's current price.
View analysts price targets for MESO or view top-rated stocks among Wall Street analysts.
How have MESO shares performed in 2024?: Mesoblast's stock was trading at $2.20 at the start of the year. Since then, MESO stock has increased by 135.0% and is now trading at $5.17.
View the best growth stocks for 2024 here.
Are investors shorting Mesoblast?: Mesoblast saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,340,000 shares, an increase of 190.1% from the March 15th total of 806,500 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is presently 1.1 days.
View Mesoblast's Short Interest.
When is Mesoblast's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our MESO earnings forecast.
How were Mesoblast's earnings last quarter?: Mesoblast Limited (NASDAQ:MESO) announced its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The firm had revenue of $2.14 million for the quarter, compared to the consensus estimate of $2 million.

When did Mesoblast's stock split?: Shares of Mesoblast reverse split on Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.
What other stocks do shareholders of Mesoblast own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).
When did Mesoblast IPO?: Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.
How do I buy shares of Mesoblast?: Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MESO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial